Marina Elena C.
- Country
- Italy
- Department
- Medical Oncologist
Research Overview
- Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Phase I Study of OKI-219 Monotherapy and in Combination with Endocrine or HER2-Targeted Therapy in Advanced Solid Tumors and Breast Cancer
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 585 of 922 partner sites.
Specializations
Non-Small Cell Lung Cancer (NSCLC)
The investigator specializes in the treatment of non-small cell lung cancer across various stages and presentations, with particular focus on both early-stage resectable disease and advanced metastatic cases.
- Resectable NSCLC (Stages IIA to IIIB)
- Metastatic NSCLC with PD-L1 expression
- EGFR-mutated NSCLC
Expertise extends to both squamous and non-squamous NSCLC variants, incorporating targeted and immunotherapy approaches.
Specialized Lung Cancer Subtypes
The investigator focuses on distinct lung cancer subtypes requiring specialized therapeutic approaches, including large-cell neuroendocrine carcinoma and specific genetic mutations.
- Pulmonary LCNEC
- HER2-mutated lung cancer
- EGFR Exon 20 insertion mutations
Treatment strategies encompass both conventional and innovative therapeutic combinations.
Immunotherapy Applications
The investigator has extensive experience in immunotherapy treatments for lung cancer, particularly focusing on immune checkpoint inhibitors and combination approaches.
- PD-1/PD-L1 inhibitor therapy
- Neoadjuvant immunotherapy
- Maintenance therapy strategies
Research includes both single-agent immunotherapy and combinations with chemotherapy or targeted agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.